The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
How Will The Market Size Of The Non-injectable Insulin Market Evolve From 2026 To 2030?
The non-injectable insulin market size has seen robust expansion in recent years. It is anticipated to increase from $2.14 billion in 2025 to $2.35 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.9%. The market’s past growth can be attributed to the rising prevalence of diabetes, an increased patient preference for non-injective therapies, continuous advancements in insulin formulation, government initiatives aimed at fostering diabetes care, and heightened awareness concerning diabetes complications.
The non-injectable insulin market is anticipated to show significant expansion over the next few years, with its valuation expected to reach $3.41 billion by 2030, growing at a compound annual growth rate (CAGR) of 9.8%. This projected growth is largely due to factors such as technological progress in oral and inhalable insulin, the adoption of digital health solutions, an aging global population, the expansion of healthcare infrastructure in developing economies, and tailored medicine approaches for diabetes care. Important trends foreseen in this period include the development of oral insulin delivery systems, pulmonary insulin inhalers, patient-centric diabetes management, non-invasive monitoring and dosing techniques, and innovative formulations aimed at improving bioavailability.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13888&type=smp
What Key Drivers Are Influencing The Growth Of The Non-injectable Insulin Market?
The increasing prevalence of obesity and diabetes is anticipated to fuel the expansion of the non-injectable insulin market in the coming years. Obesity involves the excessive buildup of body fat, typically stemming from an imbalance in energy consumption versus expenditure, whereas diabetes mellitus, commonly known as diabetes, describes metabolic conditions marked by persistently elevated blood sugar. Non-injectable insulin serves as a treatment for both diabetes and obesity, potentially enhancing management by overcoming obstacles to traditional insulin therapy, offering advantages for weight control, and delivering more user-friendly treatment alternatives. For instance, in June 2023, the Institute for Health Metrics and Evaluation, a US-based public health research institute, reported that over half a billion people globally were living with diabetes. This figure is projected to more than double, reaching 1.3 billion people by 2050. Consequently, the escalating concerns regarding obesity and diabetes are propelling the growth of the non-injectable insulin market.
Which Segment Areas Are Covered In The Non-injectable Insulin Market Analysis?
The non-injectable insulin market covered in this report is segmented –
1) By Insulin Type: Oral Insulin, Inhaled Insulin, Nasal Insulin, Buccal Or Sublingual Insulin, Transdermal Insulin
2) By Product: Pills, Sprays, Other Products
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Drug Stores
Subsegments:
1) By Oral Insulin: Oral Insulin Tablets, Oral Insulin Capsules, Enteric-Coated Oral Insulin, Nanoparticle-Based Oral Insulin
2) By Inhaled Insulin: Dry Powder Inhaled Insulin, Aerosolized Insulin, Pulmonary Insulin Delivery Systems
3) By Nasal Insulin: Nasal Spray Insulin, Nasal Gel Insulin, Nasal Powder Insulin
4) By Buccal Or Sublingual Insulin: Buccal Spray Insulin, Sublingual Insulin Films, Oral Mucosal Insulin Drops
5) By Transdermal Insulin: Insulin Patches, Microneedle-Free Transdermal Systems, Iontophoresis-Based Insulin Delivery
What Key Developments And Trends Are Impacting The Non-injectable Insulin Market?
Leading companies in the non-injectable insulin market are concentrating on groundbreaking advancements in drug delivery systems, such as needle-free oral insulin sprays, to enhance the lives of individuals who manage their diabetes with multiple insulin injections. A needle-free insulin spray offers a painless and non-invasive way to regulate blood glucose, providing a convenient choice as doses can be sprayed directly into the mouth. For example, NiedlFree Technologies, an India-based technology platform, unveiled Ozulin, an oral insulin spray, in November 2023. This oral insulin spray aims to provide a more accessible solution for people with diabetes, especially those who find traditional injectable insulin methods difficult. If it gains approval, Ozulin could significantly change diabetes management by offering a more convenient and pain-free alternative to insulin injections.
Which Global Companies Are Actively Competing In The Non-injectable Insulin Market?
Major companies operating in the non-injectable insulin market are Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Pfizer Inc., Novartis AG, Merck & Co. Inc., AstraZeneca, Takeda Pharmaceutical, Abbott Laboratories, MannKind Corporation, Biocon Limited, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Limited, Cipla Limited, Lupin Pharmaceuticals, Glenmark Pharmaceuticals, Torrent Pharmaceuticals, Wockhardt Limited, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd.
Read the full non-injectable insulin market report here:
https://www.thebusinessresearchcompany.com/report/non-injectable-insulin-global-market-report
Which Region Is Expected To Register The Fastest Growth In The Non-injectable Insulin Market?
North America was the largest region in the non-injectable insulin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-injectable insulin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Non-injectable Insulin Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=13888&type=smp
Browse Through More Reports Similar to the Global Non-injectable Insulin Market 2026, By The Business Research Company
Non Injectable Insulin Market Report 2026
https://www.thebusinessresearchcompany.com/report/non-injectable-insulin-global-market-report
Insuman Market Report 2026
https://www.thebusinessresearchcompany.com/report/insuman-global-market-report
Oem Insulation Market Report 2026
https://www.thebusinessresearchcompany.com/report/oem-insulation-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model